Insider Selling: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells 11,119 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Donald Notman sold 11,119 shares of Ocular Therapeutix stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the sale, the insider now directly owns 193,444 shares in the company, valued at $1,510,797.64. This trade represents a 5.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Donald Notman also recently made the following trade(s):

• On Friday, January 31st, Donald Notman sold 6,301 shares of Ocular Therapeutix stock. The shares were sold at an average price of $7.84, for a total value of $49,399.84.

Ocular Therapeutix Stock Up 4.0 %

Shares of Ocular Therapeutix stock opened at $8.13 on Thursday. The business has a 50-day moving average price of $8.57 and a 200 day moving average price of $9.01. Ocular Therapeutix, Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $11.77. The firm has a market cap of $1.28 billion, a P/E ratio of -6.16 and a beta of 1.22. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. Scotiabank initiated coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.71.

Institutional Investors Weigh In On Ocular Therapeutix

A number of institutional investors have recently made changes to their positions in OCUL. Charles Schwab Investment Management Inc. boosted its holdings in Ocular Therapeutix by 146.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock worth $9,661,000 after purchasing an additional 660,080 shares during the period. Patient Square Capital LP bought a new position in shares of Ocular Therapeutix in the 3rd quarter worth about $2,049,000. Polar Asset Management Partners Inc. acquired a new position in shares of Ocular Therapeutix in the 3rd quarter valued at about $4,288,000. SG Americas Securities LLC bought a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at about $393,000. Finally, FMR LLC grew its position in shares of Ocular Therapeutix by 7,098.7% during the 3rd quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock valued at $3,779,000 after buying an additional 428,335 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.